Phase 1 Study of UB-VV111 for Relapsed/Refractory B-cell Malignancies
This is a Phase 1 study testing UB-VV111, a gene therapy that helps your body create its own CAR T cells (a type of immune cell that fights cancer), with or without rapamycin, an FDA-approved drug. This study is for adults aged 18 or older who have large B-cell lymphoma (LBCL) or chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. The main goal is to see how safe UB-VV111 is and what side effects it might cause. Researchers will also look at how well it works against cancer. This study plans to enroll 106 participants, but its current recruitment status is unclear.
- Study design
- This is a Phase 1 study designed to find the right dose and confirm the safety and anti-tumor activity of UB-VV111. It plans to enroll 106 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for common side effects for up to 2 years after receiving UB-VV111.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
At a glance
Conditions
NCT06528301
Where you'd take part
This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
City of Hope
Duarte, Californiastudy coordinator listed
Not yet recruiting
Fred Hutch Cancer Center
Seattle, Washingtonstudy coordinator listed
Recruiting
Royal North Shore Hospital
Saint Leonards, New South Wales, Australiastudy coordinator listed
Recruiting
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, Australiastudy coordinator listed
Recruiting
The David and Etta Jonas Center for Cellular Therapy
Chicago, Illinoisstudy coordinator listed
Recruiting
University of Cincinnatti Medical Center
Cincinnatti, Ohiostudy coordinator listed
Recruiting
University of Nebraska Medical Center
Omaha, Nebraskastudy coordinator listed
Recruiting
Washington University School of Medicine/Siteman Cancer Center
St Louis, Missouristudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Luke Walker, MD · STUDY_DIRECTOR · Umoja Biopharma
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percentage of participants with common adverse events (AEs)Up to 2 years after UB-VV111 administration
Percentage of participants with commonly reported AEs overall and by severity